SANA BIOTECHNOLOGY INC (SANA)
US7995661045 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to SANA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.39. This target is 16.46% above the current price.
SANA was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about SANA.
In the previous month the buy percentage consensus was at a similar level.
SANA was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-01 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-16 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2023-10-12 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-09-25 | JMP Securities | Initiate | Market Outperform |
| 2023-09-05 | Citigroup | Initiate | Buy |
| 2023-08-14 | TD Cowen | Initiate | Market Perform |
| 2023-05-02 | HC Wainwright & Co. | Initiate | Neutral |
| 2023-01-24 | Morgan Stanley | Maintains | Overweight |
| 2022-11-03 | Goldman Sachs | Maintains | Neutral |
| 2022-05-17 | Morgan Stanley | Maintains | Overweight |
| 2021-08-06 | Goldman Sachs | Maintains | Neutral |
| 2021-03-01 | JP Morgan | Initiate | Neutral |
| 2021-03-01 | Goldman Sachs | Initiate | Neutral |
| 2021-03-01 | Morgan Stanley | Initiate | Overweight |